#1 Clinical Trials Search in Europe

Anti-Human T-Lymphocyte Immunoglobulin From Rabbits

This article summarizes several clinical trials investigating the use of anti-human T-lymphocyte immunoglobulin from rabbits (also known as rabbit anti-thymocyte globulin or ATG) for treating various medical conditions. The trials are examining ATG’s potential in kidney transplantation, graft-versus-host disease prevention, stem cell transplantation, systemic sclerosis, and type 1 diabetes. ATG works by suppressing the immune system and is being studied to see if it can improve outcomes in these immune-related disorders.

Table of Contents

What is Anti-Human T-Lymphocyte Immunoglobulin?

Anti-human T-lymphocyte immunoglobulin from rabbits, also known as rabbit anti-thymocyte globulin (rATG) or by brand names like Thymoglobulin or Grafalon, is a type of medication used to suppress the immune system[1]. It is made from antibodies produced by rabbits that target human T cells, which are a key part of the immune system.

How Does It Work?

This medication works by targeting and reducing the number of T cells in the body. T cells are white blood cells that play a crucial role in the immune system’s response. By decreasing T cells, anti-human T-lymphocyte immunoglobulin helps to suppress the immune system’s activity[2]. This can be beneficial in certain medical situations where an overactive immune response needs to be controlled.

What Is It Used For?

Anti-human T-lymphocyte immunoglobulin is used in several medical scenarios, including:

  • Organ Transplantation: It helps prevent rejection of transplanted organs by suppressing the immune system’s response to the new organ[1].
  • Graft-versus-Host Disease (GVHD) Prevention: In stem cell transplants, it can help prevent or treat GVHD, a condition where transplanted cells attack the recipient’s body[2].
  • Autoimmune Disorders: It may be used in some severe cases of autoimmune diseases where the immune system attacks the body’s own tissues[3].
  • Aplastic Anemia: A condition where the bone marrow doesn’t produce enough new blood cells[2].

How Is It Administered?

Anti-human T-lymphocyte immunoglobulin is typically administered through intravenous infusion, which means it’s given directly into a vein. The dosage and duration of treatment can vary depending on the specific medical condition and individual patient factors. Some key points about administration include:

  • It’s usually given in a hospital or clinical setting under close medical supervision.
  • The infusion may be given over several hours and might be repeated for multiple days.
  • Doses are often calculated based on the patient’s weight.
  • Premedication with corticosteroids, antihistamines, or acetaminophen may be given to reduce the risk of infusion reactions[4].

Potential Side Effects

As with any powerful medication that affects the immune system, anti-human T-lymphocyte immunoglobulin can have side effects. Some potential side effects include:

  • Infusion reactions: Fever, chills, nausea, headache, or skin rashes during or shortly after the infusion.
  • Increased risk of infections: Due to the suppressed immune system, patients may be more susceptible to various infections.
  • Blood disorders: Changes in blood cell counts, including anemia or low platelet counts.
  • Allergic reactions: In rare cases, severe allergic reactions can occur.
  • Serum sickness: A delayed type of allergic reaction that can cause fever, rash, and joint pain.

It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms promptly[1].

Precautions and Considerations

Before receiving anti-human T-lymphocyte immunoglobulin, patients should be aware of several important factors:

  • Allergies: Inform your doctor if you have any known allergies, especially to rabbit proteins.
  • Infections: Any active infections should be treated before starting this medication.
  • Vaccinations: Live vaccines should be avoided while on this treatment and for some time afterward.
  • Pregnancy and breastfeeding: The safety of this medication during pregnancy or breastfeeding is not well established, so discuss this with your doctor if applicable.
  • Long-term effects: The medication can affect your immune system for an extended period, so follow-up care and monitoring are important[4].

Ongoing Research

Researchers continue to study anti-human T-lymphocyte immunoglobulin to understand its full potential and optimize its use. Some areas of ongoing research include:

  • Type 1 Diabetes: Studies are exploring its use in newly diagnosed type 1 diabetes to potentially preserve beta cell function[5].
  • Stem Cell Transplantation: Research is ongoing to refine its use in preventing graft-versus-host disease in various transplant scenarios[6].
  • Autoimmune Diseases: Its potential in treating severe cases of autoimmune disorders is being investigated[3].

As with any medical treatment, the use of anti-human T-lymphocyte immunoglobulin should be carefully considered and discussed with your healthcare provider. They can provide personalized information based on your specific medical situation and help you weigh the potential benefits against the risks.

Trial Focus Condition Key Points
Kidney Transplant in Children Highly sensitized pediatric patients – Testing imlifidase and ATG for crossmatch conversion
– Aims to improve transplant success in difficult-to-match patients
Graft-versus-Host Disease Prevention Patients undergoing allogeneic stem cell transplant – Comparing ATG-thymoglobulin to ATLG-grafalon
– Assessing effectiveness in preventing GVHD
Stem Cell Transplantation Acute myeloid leukemia or myelodysplastic syndrome – Testing different conditioning regimens with ATG
– Evaluating outcomes in elderly patients
Systemic Sclerosis Treatment Early diffuse cutaneous systemic sclerosis – Comparing stem cell transplantation with ATG to conventional therapy
– Assessing disease progression and organ function
Type 1 Diabetes Recent-onset type 1 diabetes in children and young adults – Testing Grafalon (ATG) to preserve beta cell function
– Evaluating impact on insulin needs and diabetes markers

FAQ

  • What is anti-human T-lymphocyte immunoglobulin from rabbits? Anti-human T-lymphocyte immunoglobulin from rabbits, also known as rabbit anti-thymocyte globulin (ATG), is a medication that suppresses the immune system. It is made from antibodies produced by rabbits that target human T cells, which are important immune cells.
  • What conditions are being studied using this medication in these trials? The clinical trials are investigating the use of this medication for kidney transplantation in children, prevention of graft-versus-host disease in stem cell transplants, treatment of systemic sclerosis, and preserving beta cell function in recent-onset type 1 diabetes.
  • How is the medication administered in these trials? The medication is typically administered intravenously (through an IV) as an infusion. The dosage and schedule vary between trials, but it is often given over several days as part of a conditioning regimen before transplantation or as a treatment course.
  • What are some potential side effects of this medication? Potential side effects can include infections, allergic reactions, fever, and changes in blood cell counts. The trials are monitoring patients closely for any adverse events. As it suppresses the immune system, there is an increased risk of infections.
  • Why is this medication being studied for these conditions? This medication is being studied because of its ability to suppress the immune system. In transplantation, it may help prevent rejection of the new organ or graft-versus-host disease. In autoimmune conditions like type 1 diabetes, it may help slow down the immune attack on the body's own cells.

Ongoing Clinical Trials on Anti-Human T-Lymphocyte Immunoglobulin From Rabbits

  • Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Graft-Versus-Host Disease Prevention Using Cyclophosphamide and Methotrexate in Adults with Blood Cancer Undergoing Matched-Donor Transplant

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Imlifidase and Drug Combination for Kidney Transplant in Highly Sensitized Children

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Spain Sweden

  • Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

    Recruiting

    4 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

Glossary

  • Anti-human T-lymphocyte immunoglobulin: A medication made from antibodies produced by rabbits that target human T cells, used to suppress the immune system.
  • Graft-versus-host disease (GVHD): A complication that can occur after a stem cell or bone marrow transplant where the donor cells attack the recipient's body.
  • Systemic sclerosis: An autoimmune disease that causes hardening and tightening of the skin and can affect internal organs.
  • Type 1 diabetes: An autoimmune condition where the body's immune system attacks and destroys insulin-producing cells in the pancreas.
  • Beta cell: A type of cell in the pancreas that produces insulin.
  • Allogeneic stem cell transplantation: A procedure where stem cells from a donor are transplanted into a recipient to treat certain blood and immune system disorders.
  • Conditioning regimen: A treatment plan, often involving chemotherapy and/or radiation, used to prepare a patient's body for a stem cell transplant.
  • Immunosuppression: The purposeful reduction of immune system activity, often used to prevent rejection in organ transplants or to treat autoimmune diseases.
  • Acute myeloid leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by rapid growth of abnormal white blood cells.
  • Myelodysplastic syndrome (MDS): A group of disorders where blood cells in the bone marrow do not mature properly.
  • HLA matching: The process of finding a donor whose human leukocyte antigens (HLA) are compatible with the recipient's, important for transplant success.
  • Crossmatch: A test to determine if a recipient has antibodies against a potential donor's cells, used to assess compatibility for transplantation.
  • Panel reactive antibodies (PRA): A measure of how reactive a recipient's immune system is against a panel of potential donors, used to assess the difficulty of finding a compatible organ.
  • Glomerular filtration rate (GFR): A measure of how well the kidneys are filtering waste from the blood.
  • Minimal residual disease (MRD): The small number of cancer cells that may remain after treatment, often undetectable by standard tests.

References

  1. http://clinicaltrials.eu/trial/study-on-imlifidase-and-drug-combination-for-kidney-transplant-in-highly-sensitized-children/
  2. http://clinicaltrials.eu/trial/study-comparing-thymoglobulin-and-grafalon-for-preventing-graft-versus-host-disease-in-elderly-patients-with-acute-myeloid-leukemia-or-myelodysplastic-syndrome/
  3. http://clinicaltrials.eu/trial/study-on-early-diffuse-cutaneous-systemic-sclerosis-comparing-stem-cell-transplantation-with-cyclophosphamide-filgrastim-and-mycophenolate-mofetil/
  4. http://clinicaltrials.eu/trial/study-on-graft-versus-host-disease-prevention-using-cyclophosphamide-and-methotrexate-in-adults-with-blood-cancer-undergoing-matched-donor-transplant/
  5. http://clinicaltrials.eu/trial/study-on-anti-t-lymphocyte-immunoglobulin-for-children-and-young-adults-with-recent-type-1-diabetes-to-preserve-beta-cell-function/
  6. http://clinicaltrials.eu/trial/study-on-conditioning-treatments-with-busulfan-clofarabine-and-fludarabine-for-children-with-acute-myeloid-leukemia-undergoing-stem-cell-transplantation/